Radicava (also known as Edaravone)
Radicava is an antioxidant and theorized to reduce oxidative stress, which is a process central to neuronal death in Amyotrophic Lateral Sclerosis (ALS). In a phase 3 clinical trial in Japan and South Korea, 137 patients with ALS were administered Radicava or Placebo; the patients who received Radicava experienced significantly less deterioration in physical abilities compared to the placebo group.
FDA approved since May 2017 for patients with Amyotrophic Lateral Sclerosis (ALS), especially early stage.
Patients with allergies to Sodium Bisulfite should not start on Radicava.
Radicava is recommended to be administered by 1 hour intravenous infusion daily for 14 days for the first cycle, followed by 14 day rest. Subsequent cycles are infused daily for 10 days, followed by at least a 14 day rest.